ADAP(Delisted)
AdaptimmuneยทNASDAQ
--
--(--)
ADAP Profile
Adaptimmune Therapeutics Plc
A leader in cell therapy to treat cancer
--
12/03/2014
05/06/2015
NASDAQ Stock Exchange
506
12-31
Depository Receipts (Ordinary Shares)
60 Jubilee Avenue, Milton Park, Abingdon, OxfordshireOX14 4RX, United Kingdom
--
Adaptimmune Therapeutics Plc was established on 3 December 2014 and is a public limited company incorporated under the laws of England and Wales. The company is a clinical-stage biopharmaceutical company that will transition to a commercial-stage cell therapy company in 2024. The company focuses on providing novel cell therapies to cancer patients. The company's first product, afamitresgene autoleucel or "afami-cel" is unique to synovial sarcoma and will be the first product in the sarcoma product franchise. The Lete-cel, which they plan to launch commercially in the US in 2026, will be the second product in the sarcoma franchise and will target both synovial sarcoma and myxoid round cell liposarcoma, significantly expanding the treatable patient population.
